D46.21

Clinical Causes: Genetic mutations or chromosomal abnormalities Environmental exposures such as radiation or chemotherapy Certain inherited syndromes Previous treatment with radiation or chemotherapy for other cancers Idiopathic factors, where the cause is unknown

Key Symptoms: Fatigue and weakness due to anemia Shortness of breath during exertion Unusual bleeding or bruising Increased susceptibility to infections Pale skin Frequent or severe infections Unintended weight loss Fever without an identifiable cause

Diagnosis Path: Diagnosis of RAEB 1 involves a combination of blood tests and bone marrow examination. Initial blood work often reveals anemia, low platelet counts, and abnormal white blood cell levels. A bone marrow biopsy provides detailed insight into the marrow's cellular composition, showing increased blasts (immature blood cells) between 5% and 9% of all marrow cells, which is characteristic of RAEB 1. Cytogenetic analysis may also be performed to detect chromosomal abnormalities associated with the disorder. Other tests may include flow cytometry and molecular studies to better understand the disease's genetic profile.

Treatment Protocols: Treatment strategies for RAEB 1 aim to manage symptoms, prevent disease progression, and improve quality of life. These may include supportive therapies such as blood transfusions to address anemia and bleeding. Hematopoietic growth factors, such as erythropoietin, can sometimes stimulate red blood cell production. Disease-modifying treatments include hypomethylating agents like azacitidine or decitabine, which can help control abnormal cell growth. In cases where the disease progresses or does not respond to medication, stem cell transplantation may be considered. Regular monitoring is essential to assess disease progression and adjust therapies accordingly.